As there is currently no available RPIA inhibitor, our study aimed to identify additional targetable nucleotide metabolism pathways that are specifically vulnerable to inhibition in cancers with low p16/CDKN2A expression (p16/CDKN2Alow). The gene discussed is CDKN2A; the disease is cancer.